Fig. 2

Targeting different TME components for cancer therapy: Current strategies available for targeting major TME components for effective cancer therapy are shown. A Targeting inflammation, B targeting hypoxic TME, C targeting TME nerve supply, D targeting TME vascularization and cellular components like E targeting cancer associated fibroblasts (CAFs), targeting innate immune components by F Inducing M1Polarization, G Inhibiting M2 Polarization, H targeting Neutrophils, I targeting Natural Killer cells, J targeting Dendritic cells, and targeting adaptive immune components by K Activation of CTLs and L Targeting B cells are promising targets. Various drugs/inhibitors/antibodies targeting these components are in preclinical studies, under clinical trial or FDA approved for cancer treatment. The figure is prepared by using BioRender software and publication license is obtained